Expression of melanocortin receptors in human prostate cancer cell lines: MC2R activation by ACTH increases prostate cancer cell proliferation.
暂无分享,去创建一个
A. Abdel‐Mageed | D. Schwartz | R. Judd | B. Akingbemi | E. Morrison | Y. Tao | J. Dennis | M. Mansour | S. Hafiz | Kamel F. Khazal | Xiu-Lei Mo | K. Khazal
[1] D. Coy,et al. Investigation of cancer cell lines for peptide receptor-targeted drug development , 2011, Journal of drug targeting.
[2] N. Gallo‐Payet,et al. Adrenocorticotropin hormone (ACTH) effects on MAPK phosphorylation in human fasciculata cells and in embryonic kidney 293 cells expressing human melanocortin 2 receptor (MC2R) and MC2R accessory protein (MRAP)β , 2011, Molecular and Cellular Endocrinology.
[3] D. Merkle,et al. Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: cross-talk with the androgen receptor. , 2011, Cellular signalling.
[4] Mahmoud Mansour,et al. Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer. , 2011, International journal of oncology.
[5] E. Morrison,et al. Pancreatic neuronal melanocortin-4 receptor modulates serum insulin levels independent of leptin receptor , 2010, Endocrine.
[6] A. Vis,et al. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways , 2009, BJU international.
[7] M. M. Nguyen,et al. Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer. , 2008, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.
[8] N. Gallo‐Payet,et al. Differential regulation of the human adrenocorticotropin receptor [melanocortin-2 receptor (MC2R)] by human MC2R accessory protein isoforms alpha and beta in isogenic human embryonic kidney 293 cells. , 2007, Molecular endocrinology.
[9] J. Brooks,et al. A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells , 2007, Nucleic acids research.
[10] J. Gutkind,et al. G-protein-coupled receptors and cancer , 2007, Nature Reviews Cancer.
[11] Michael Ittmann,et al. The prostate‐specific G‐protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to α‐methylacyl‐CoA racemase , 2006, The Prostate.
[12] R. Cone. Studies on the physiological functions of the melanocortin system. , 2006, Endocrine reviews.
[13] P. Casey,et al. Androgen Receptor Activation by Gs Signaling in Prostate Cancer Cells* , 2005, Journal of Biological Chemistry.
[14] M. Ittmann,et al. Increased expression of prostate‐specific G‐protein‐coupled receptor in human prostate intraepithelial neoplasia and prostate cancers , 2005, International journal of cancer.
[15] T. Visakorpi,et al. Alterations of androgen receptor in prostate cancer , 2004, The Journal of Steroid Biochemistry and Molecular Biology.
[16] D. Tindall,et al. Mechanisms of androgen-refractory prostate cancer. , 2004, The New England journal of medicine.
[17] Y. Daaka. G Proteins in Cancer: The Prostate Cancer Paradigm , 2004, Science's STKE.
[18] Y. Daaka,et al. G protein-coupled receptors provide survival signals in prostate cancer. , 2002, Clinical prostate cancer.
[19] G. Raj,et al. Guanosine phosphate binding protein coupled receptors in prostate cancer: a review. , 2002, The Journal of urology.
[20] D. Tindall,et al. Androgen receptor signaling in androgen-refractory prostate cancer. , 2001, Journal of the National Cancer Institute.
[21] R. Strange,et al. Prostate cancer risk: associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes , 2001, British Journal of Cancer.
[22] D. Feldman,et al. The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.
[23] Fen Wang,et al. Identification of a prostate-specific G-protein coupled receptor in prostate cancer , 2001, Oncogene.
[24] B. Wisse,et al. Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. , 2001, Endocrinology.
[25] J. Gutkind,et al. G-protein-coupled receptors and signaling networks: emerging paradigms. , 2001, Trends in pharmacological sciences.
[26] J. Gutkind. Regulation of Mitogen-Activated Protein Kinase Signaling Networks by G Protein-Coupled Receptors , 2000, Science's STKE.
[27] Noah Craft,et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.
[28] S. Melmed. Pathogenesis of pituitary tumors. , 1999, Endocrinology and metabolism clinics of North America.
[29] P. Kantoff,et al. Management of hormone refractory prostate cancer: current standards and future prospects. , 1998, The Journal of urology.
[30] Ximena Opitz-Araya,et al. Exocrine Gland Dysfunction in MC5-R-Deficient Mice: Evidence for Coordinated Regulation of Exocrine Gland Function by Melanocortin Peptides , 1997, Cell.
[31] S. Woolf. Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. , 1995, The New England journal of medicine.
[32] S. Boyce,et al. Mitogenic and melanogenic stimulation of normal human melanocytes by melanotropic peptides. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[33] J. Simard,et al. Science behind total androgen blockade: from gene to combination therapy. , 1993, Clinical and investigative medicine. Medecine clinique et experimentale.
[34] M. Campbell,et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. , 1992, Cancer research.
[35] K. Kovacs,et al. Ectopic ACTH syndrome: clinicopathological correlations. , 1978, Journal of clinical pathology.
[36] R. Yalow,et al. Ectopic ACTH production in carcinoma of the lung. , 1974, The Journal of clinical investigation.
[37] W. Nicholson,et al. Nonpituitary neoplasms and Cushing's syndrome. Ectopic "adrenocorticotropin" produced by nonpituitary neoplasms as a cause of Cushing's syndrome. , 1963, Archives of internal medicine.
[38] G. Nikiforovich,et al. Constitutive activity of neural melanocortin receptors. , 2010, Methods in enzymology.
[39] M. O. Aken,et al. Cushing’s syndrome due to ectopic ACTH production by (neuroendocrine) prostate carcinoma , 2008, Pituitary.
[40] A. Armstrong,et al. Current standard and investigational approaches to the management of hormone-refractory prostate cancer. , 2007, Reviews in urology.
[41] H. Klocker,et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. , 1994, Cancer research.
[42] Halkerston Id. Cyclic AMP and adrenocortical function. , 1975 .
[43] C. Huggins. Endocrine-induced regression of cancers. , 1967, Science.